...MediGene sold Cowen Healthcare Royalty Partners a 2% royalty on European sales of Eligard leuprolide for $17.7 million in...
...Phase II trials in triple-negative breast cancer and pancreatic cancer. MediGene AG (Xetra:MDG), Martinsried, Germany Cowen Healthcare Royalty Partners...

...million, plus royalties. MediGene AG (Xetra:MDG) was up €0.04 to €1.17 last week after selling Cowen Healthcare Royalty Partners...

...MediGene AG (Xetra:MDG) sold Cowen Healthcare Royalty Partners a 2% royalty on European sales of Eligard leuprolide for $17.7...

...Mass. Business: Inflammation, Ophthalmic, Antibodies Date completed: 1/4/12 Type: Debt financing Raised: $20 million Investor: Cowen Healthcare Royalty Partners...

...The $1 billion close for Cowen Healthcare Royalty Partners ' second fund makes it crystal clear that LPs want...

...Cowen Healthcare Royalty Partners closed its second fund, Cowen Healthcare Royalty Partners II, at $1 billion. The firm said...
...Suisse was an advisor and placement agent. Cowen Royalty has over $1.5 billion under management. Cowen Healthcare Royalty Partners...

...Cowen Healthcare Royalty Partners closed its second fund, Cowen Healthcare Royalty Partners II, at $1 billion. The firm said...

...a subsidiary of Shionogi & Co. Ltd. (Tokyo:4507; Osaka:4507, Osaka, Japan), under a 2007 deal. Cowen Healthcare Royalty Partners...

...San Diego, Calif. Business: Neurology Date completed: 6/30/11 Type: Debt financing Raised: $30 million Investor: Cowen Healthcare Royalty Partners...

...Private placement Raised: $1.5 million Shares: 388,601 Price: $3.86 Shares after offering: 34.4 million Investor: Cowen Healthcare Royalty Partners...